The Man Who Lived 555 Days Without a Real Heart

555 days without a biological heart — and during part of that time, Stan Larkin was shooting basketball. The SynCardia Total Artificial Heart kept his blood moving; a 13.5-pound backpack kept the device running. Medicine had produced bridge-to-transplant cases before. It had not produced this one.

In 2014, surgeons at the University of Michigan’s Frankel Cardiovascular Center removed Stan Larkin’s failing heart entirely and replaced it with a mechanical substitute. His brother Dominique had already walked the same terrifying road. The Larkin case didn’t just push the boundaries of cardiac medicine — it forced doctors, ethicists, and patients toward a question nobody had quite faced at this scale before: where does the machine end and the person begin?

When Surgeons Remove the Heart Entirely

Most people imagine heart surgery as a repair job — bypasses, valves, stents. What happened to Stan Larkin was categorically different. The surgical team at the University of Michigan removed his natural heart and implanted the SynCardia Total Artificial Heart, a pneumatically driven device that replaced both ventricles simultaneously. This is a critical distinction. Most mechanical heart devices assist a struggling heart; the SynCardia Total Artificial Heart replaces it entirely.

Stan had biventricular heart failure — both sides of the pump had collapsed — leaving transplant surgeons no other viable bridge option. The device weighs roughly 160 grams and generates a cardiac output of up to 9.5 liters per minute, approximating the performance range of a healthy adult heart.

No human organ. Just engineering.

Biventricular failure is the kind of diagnosis that ends conversations quickly in a cardiology office. Both chambers responsible for pushing blood through the lungs and body have failed simultaneously. Ventricular assist devices — more commonly used — typically support only one side. When both sides collapse, the options narrow to near zero, and that’s where the SynCardia device stepped in. Not as a repair. As a complete mechanical substitution. That difference isn’t cosmetic — it changes everything about how the patient is monitored, powered, and eventually sent home.

Stan was in his mid-twenties when this happened. Two young men from the same family, both living without biological hearts — that detail alone stopped medical staff in their tracks.

The Backpack That Kept a Man Alive

Here’s the thing: for decades, the pneumatic driver powering devices like the SynCardia Total Artificial Heart was a refrigerator-sized hospital unit. Patients were tethered to the wall. Then came the Freedom Portable Driver — 13.5 pounds, engineered to fit inside a standard backpack — and the calculus changed entirely. A patient managing a device of this complexity outside a hospital is, in effect, carrying an ICU function in a bag. Stan Larkin did exactly that, navigating ordinary life while the backpack kept his blood moving, and there’s something in that image that can make you forget how technically staggering the underlying reality actually is.

Two percutaneous drivelines — tubes exiting through the patient’s abdomen — connect the Freedom driver to the device’s pneumatic chambers. Precisely timed bursts of air, one to each ventricle, alternate at a programmed rate. In Stan’s case, this replaced the electrical impulses a biological heart would generate independently. Battery life allows roughly four to six hours of use before recharging, meaning patients manage their power supply the way most people manage a smartphone. Except the stakes are incomparable.

Stan didn’t just tolerate this arrangement. By multiple accounts, he embraced it. That image of him shooting hoops, backpack strapped on, no detectable heartbeat — it encapsulates exactly what the engineers who designed the Freedom driver were hoping for when they built it.

Bridging the Gap Between Failure and Transplant

Why does this matter? Because 555 days is a long bridge — and not every patient survives the wait.

The medical term for what the SynCardia device does in cases like Stan’s is “bridge to transplant.” According to data published by Science.org, wait times for donor hearts in the United States can stretch well beyond a year, depending on blood type, body size, and geographic donor availability. In 2023, roughly 3,500 heart transplants were performed in the United States, while thousands more patients remained on waiting lists. The organ shortage isn’t a minor administrative problem — it is structural, and it is not closing quickly. Mechanical cardiac support, particularly the SynCardia Total Artificial Heart, exists precisely because that gap can be fatal without intervention.

And yet what’s counterintuitive here is that the SynCardia device doesn’t try to mimic the biological heart’s elegance. It doesn’t respond dynamically to emotional states or physical exertion the way a real heart does through the autonomic nervous system. Instead, it runs at a fixed rate, with output adjustable by clinicians. That Stan could play basketball with a device operating at a largely static rate tells you something remarkable about human physiological compensation — the body finds workarounds. Researchers studying the SynCardia Total Artificial Heart have noted that patients often self-regulate activity based on perceived exertion rather than heart rate, because there is no native heart rate to read (researchers actually call this “perceived exertion substitution,” and it matters more than it sounds for rehabilitation design).

That shift in how patients sense their own limits rewrites the standard rules of cardiac rehabilitation. Everything clinicians thought they understood about exercise tolerance and heart failure has to be rethought from the ground up.

SynCardia Total Artificial Heart: The Engineering Behind the Miracle

Roots of the SynCardia Total Artificial Heart stretch back to the early 1980s, when the Jarvik-7 device — its direct predecessor — was first implanted in a human patient. Dr. Barney Clark received that device at the University of Utah in 1982 and survived 112 days, a milestone that redefined what mechanical cardiac support could mean. SynCardia Systems, now headquartered in Tucson, Arizona, received FDA approval in 2004 for the device as a bridge-to-transplant therapy. Decades of iteration separated those two moments.

The device’s polyurethane ventricles and Medtronic-Hall mechanical valves are engineered to withstand hundreds of millions of compression cycles — equivalent to years of continuous use — without structural degradation. By 2016, when Stan received his transplant, more than 1,700 patients globally had been implanted with the device, across over 100 centers.

The engineering tolerance required here is staggering. A biological heart valve can flex and seal billions of times over a lifetime, repaired by living tissue and powered by a dynamic electrical system. The artificial equivalent has no self-repair mechanism — every component must simply not fail. Material science, fluid dynamics, and pneumatics all converge in a device the size of a large fist. The data left no room for skepticism about what this technology could sustain — and the engineers who built it had earned the right to say so. When you hold that context against 555 days of continuous operation, including athletic activity, “impressive” undersells it by a significant margin.

The University of Michigan team that managed Stan’s case published their findings, adding detailed observational data about long-term outpatient use of the device. Their work contributed directly to refining discharge protocols for future patients.

What Comes After: Life, Transplant, and Open Questions

Stan Larkin received a donor heart in May 2016. His brother Dominique had been transplanted earlier. Both men survived their extraordinary journeys through mechanical cardiac support and emerged with functioning biological hearts. But the story doesn’t end cleanly there, and medicine is honest enough to say so.

Long-term studies on quality of life for patients who’ve spent extended periods with the SynCardia Total Artificial Heart in outpatient settings are still accumulating. Researchers want to understand the neurological, psychological, and physiological impacts of living without a pulse — without a native cardiac rhythm — for months at a time. The body adapts; the question is how completely, and at what cost. Historical parallels exist in early dialysis patients, who lived years on machines before transplant options matured, and whose long-term outcomes informed an entire generation of nephrology practice.

Real stakes exist in getting this right. As donor organ shortages persist globally, the artificial heart’s role as a bridge device will only grow. If patients are going to spend 400, 500, even 700 days on these devices, the medical community needs rigorous data on what that does to cognition, vascular health, and psychological resilience. Blood without pulse pressure behaves differently through vessels designed for pulsatile flow. Some researchers believe extended non-pulsatile circulation may have subtle downstream effects on organs like the kidney and brain. The data is emerging, not settled.

Stan Larkin, now living with a transplanted heart, represents both the triumph and the open question — proof the technology works, and one data point in a study that’s still being written.

How It Unfolded

• 1982 — Dr. Barney Clark receives the Jarvik-7 device at the University of Utah, surviving 112 days in the first permanent artificial heart implantation in a human patient
• 2004 — SynCardia Systems receives FDA approval for the SynCardia Total Artificial Heart as a bridge-to-transplant therapy, marking the device’s transition from experimental to clinical standard
• 2014 — Stan Larkin’s biological heart is removed at the University of Michigan’s Frankel Cardiovascular Center and replaced with the SynCardia device; his brother Dominique undergoes the same procedure
• 2016 — Stan receives a donor heart transplant after 555 days on the artificial heart, with more than 1,700 patients globally having received the device by this point

By the Numbers

• 555 days — the duration Stan Larkin lived with the SynCardia Total Artificial Heart before his 2016 transplant at the University of Michigan (University of Michigan Health System, 2016)
• 13.5 pounds (6.1 kg) — weight of the Freedom Portable Driver backpack unit that powered Stan’s artificial heart outside the hospital
• 9.5 liters per minute — maximum cardiac output achievable by the SynCardia Total Artificial Heart, within the upper range of a healthy human heart at moderate exertion
• More than 1,700 patients globally had received the SynCardia Total Artificial Heart by 2016, across over 100 implant centers in multiple countries (SynCardia Systems)
• Approximately 3,500 heart transplants performed annually in the United States, against a waiting list that consistently exceeds that number (UNOS, 2023)

Field Notes

• Stan Larkin had no detectable pulse during his 555 days with the artificial heart — a fact that initially confused paramedics and emergency personnel unfamiliar with the device. He carried documentation explaining his condition at all times.
• Each pneumatic cycle of the SynCardia device produces an audible clicking sound, meaning Stan — and anyone nearby — could hear his artificial heart working. Patients report that the sound becomes background noise within weeks.
• Both Larkin brothers are believed to be the first siblings in medical history to each receive the SynCardia Total Artificial Heart as a bridge to transplant, raising questions about the genetic basis of their shared biventricular failure — a thread researchers are still pulling.
• Scientists still can’t fully explain why some patients adapt remarkably well to non-pulsatile circulation during extended artificial heart support while others show vascular strain — individual physiological variation here remains poorly understood.

Frequently Asked Questions

Q: What exactly is the SynCardia Total Artificial Heart and how does it differ from other heart devices?

FDA-approved since 2004, the SynCardia Total Artificial Heart is the only device that replaces both ventricles of a failing heart entirely, rather than assisting them. Most other mechanical cardiac devices — ventricular assist devices, or VADs — support one side of a weakened heart. The SynCardia device is used specifically in cases of biventricular failure, where both chambers have failed beyond assistance, and is approved for use as a bridge to transplant.

Q: How did Stan Larkin survive outside a hospital while using the artificial heart?

Central to that survival was the Freedom Portable Driver — a 13.5-pound pneumatic controller carried in a backpack. It delivers precisely timed bursts of compressed air through drivelines that exit the patient’s abdomen, triggering the artificial ventricles to contract and push blood through the body. Rechargeable batteries last several hours before requiring a charge cycle. Patients are trained extensively before discharge on device management, troubleshooting, and emergency protocols.

Q: Is it true patients with the artificial heart have no pulse?

Yes — and this is one of the most commonly misunderstood aspects of the technology. A natural pulse is generated by the rhythmic expansion of arterial walls in response to pulsatile blood flow from the heart’s ventricles. Because the SynCardia Total Artificial Heart operates at a fixed, continuous rate rather than generating the same dynamic wave as a biological heart, patients typically have no detectable radial pulse. Emergency responders unfamiliar with the device can misinterpret this as cardiac arrest, which is why patients carry medical identification cards explaining their condition at all times.

Stan Larkin’s story isn’t really about one man and one machine. It’s about the shrinking distance between biology and engineering — and what happens to identity, endurance, and ordinary life when that distance collapses entirely. The donor organ shortage isn’t going away. More patients will spend months, possibly years, kept alive by devices we’re still learning to understand. What does it mean to live fully while waiting for the organ that makes you whole? Stan shot hoops. That might be the most human answer medicine has ever produced.